A day after Daiichi Sankyo bought India's largest pharma company Ranbaxy, the debate has already started whether consolidation is the way going forward for pharma players, considering generics is becoming an increasingly tough business to stay invested.Margins are sliding on generic drugs and the cost on research and litigation has gone up substantially.
